Neither the 10-k nor the clinicaltrials.gov website state 1:1 ratio: they only state patients are randomized to l and p without specifying the exact ratio.

Again, the 2:1 ratio has always been communicated by the company in every PR, call and interview.

And again: per protocol, patients can continue to receive any drug they received prior to randomization, as specified in the protocol, besides leronlimab or placebo.